Immunosuppression in peripheral neuropathy: rationale and reality.
Plasma exchange, intravenous immunoglobulin and corticosteroids continue to be the mainstay of treatment for inflammatory neuropathies. Recent trials demonstrate that combining these therapies is not significantly more effective than single agent treatment. The usefulness of novel immunotherapies and cytotoxic agents is difficult to ascertain because of the treatment of small numbers of patients in open-label studies.
Sutton
Ian J
IJ
Department of Neurology, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK.
Winer
John B
JB
D000818:Animals; D003711:Demyelinating Diseases / Q000188:drug therapy; D020275:Guillain-Barre Syndrome / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016472:Motor Neuron Disease / Q000188:drug therapy; D010265:Paraproteinemias / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy*
D007166:Immunosuppressive Agents